Role of Beta Blockers in the Management of Esophageal Varices Bleeding

Mechanism of Action and Effects

Non-selective beta blockers reduce portal pressure through β1-receptor blockade, which decreases cardiac output, and β2-receptor blockade, which causes splanchnic vasoconstriction through unopposed alpha-adrenergic activity 1, 2
These effects lead to decreased portal venous inflow and lower portal pressure, with a desired reduction of 20% in portal pressure gradient achievable in 50-75% of patients with propranolol or carvedilol 2, 3
Beta blockers also reduce azygos blood flow, contributing to their effectiveness in preventing variceal bleeding 3

Beta blockers should NOT be used during acute variceal bleeding episodes as they decrease blood pressure and blunt the physiologic increase in heart rate associated with bleeding 4, 5
First-line pharmacological therapy for acute bleeding should include vasoactive drugs, such as terlipressin, somatostatin, or octreotide, started as soon as variceal bleeding is suspected, even before endoscopy 5
Short-course prophylactic antibiotics should be used to reduce infection risk and improve survival 4, 3

The combination of non-selective beta blockers plus endoscopic variceal ligation (EVL) is the best option for secondary prophylaxis of variceal hemorrhage, with rebleeding rates of 14-23% for combination therapy versus 38-47% for EVL alone 7, 8, 6, 9
The non-selective beta blocker should be titrated to the maximal tolerated dose 8
Patients who are "HVPG responders" have the lowest rebleeding rate of approximately 10% 9

Non-selective beta blockers are the gold standard for prevention of first variceal hemorrhage in patients with medium/large varices, and significantly reduce the risk of first hemorrhage in patients with large varices 8

Contraindications to beta blockers must be recognized, including hypotension, acute bleeding episodes, and other standard contraindications, such as severe bradycardia, high-degree heart block, asthma, etc. 2, 3, 4, 5, 1
The American Association for the Study of Liver Diseases recommends that beta blockers be started for secondary prophylaxis once the patient has recovered from the acute episode and before discharge from hospital 9
The European Association for the Study of the Liver suggests that beta blockers be continued indefinitely unless contraindications develop 2